| 2026-10-01 | semaglutide | Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies Paccola GP, de Oliveira RF, Mochetti MM, Razera FPM, Vecchi R, Montanher RCP. | Clin Obes |
| 2026-10-01 | semaglutide | Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis Bhaduri G, Roy S, Kalia A, Gokalani R, Saboo B. | Clin Obes |
| 2026-10-01 | semaglutide | From abdominal adiposity to liver fibrosis: Expanding promise of semaglutide for Asian Indians Ghosh A, Misra A. | Indian J Gastroenterol |
| 2026-09-03 | semaglutide | Obesity, fasting, and chronic migraine: Can semaglutide disrupt the vicious cycle? Abacıoğlu HB, Kara M, Özçakar L. | Headache |
| 2026-09-03 | semaglutide | Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities Vahora S, Shah V, Patel B. | Pharm Res |
| 2026-09-03 | liraglutide | An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product Tang Y, Bai M, Lu X, Xing X. | Pharm Res |
| 2026-09-02 | semaglutide | Late-life semaglutide treatment slows ageing and extends lifespan in female mice Feng Y, Barthez M, Wang Y, Chen Y, Qiu H, Wang CL, Heydari K, Delcroix M, Rasmussen LJ, Bohr VA, Chen D. | Nature |
| 2026-09-01 | semaglutide | Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss Murugadoss K, Venkatakrishnan AJ, Soundararajan V. | NPJ Metab Health Dis |
| 2026-09-01 | semaglutide | Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis Kow CS, Thiruchelvam K, Ramachandram DS, Zaihan AF. | Endocrinol Diabetes Metab |
| 2026-09-01 | tirzepatide | In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y Davidson MB, ACP Journal Club Editorial Team at McMaster University. | Ann Intern Med |
| 2026-09-01 | tirzepatide | Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations Zhang Y, Liu J. | Diabetes Care |
| 2026-09-01 | tirzepatide | Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide Al Ozairi E, Irshad M, Alkandri J, Mashankar A, Gray SR, le Roux CW. | Diabetes Metab Res Rev |
| 2026-09-01 | tirzepatide | Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era Mohamed ZI, Shidane AA, Abdiasis AM, Hussein MH, Ibrahim AO, Abdi AA, Hashi KI, Mohamud MA, Mohamed AJ. | Endocrinol Diabetes Metab |
| 2026-09-01 | retatrutide | Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia Piatkowski T, Craven A, Cornell S, Ferris J. | Drug Alcohol Rev |
| 2026-08-31 | tirzepatide | Tirzepatide non-response with subsequent semaglutide response in class 2 obesity La Vignera S, Condorelli RA. | JCEM Case Rep |
| 2026-08-31 | mazdutide | Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials Hassan A, Farooq QUA, Parwesh F, Rasul M, Masood A, Aftab H, Riaz H, Mahmood A, Malik MA, Rehman AU, Nenwani K, Ahmad MA, Basharat A, Rasul M, Sarwar A, Hasan AH. | F1000Res preprint |
| 2026-08-26 | retatrutide | Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis Branine N. | Cureus |
| 2026-08-25 | survodutide | Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ, SYNCHRONIZE-MASLD Investigators. | Nat Med |
| 2026-08-21 | mazdutide | Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, Haupt A, Thomas MK, Tham LS, Calderon B, Ni W, De Araujo OFG. | Lancet Diabetes Endocrinol |
| 2026-08-19 | tirzepatide | Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome Clift AK, Reisel D, Johnson H, Sattar N, Huang DR. | J Endocr Soc |
| 2026-08-19 | dulaglutide | Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA) Adly AAM, Ismail EAR, Abdel Kader MSEM, Sadeq MR, Salah NY. | Diabetologia |
| 2026-08-18 | semaglutide | Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide Rasmussen BS, Simonÿ C, Poulsen ML, Uhrenholt NG, Lundberg B, Rønne ST, Uhrenholt PG, Gæde PH, Arnfred SM. | Int J Qual Stud Health Well-being |
| 2026-08-17 | dulaglutide | Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice Wang Y, Hao D, Fan X, Pan L, Duan H, Yan J, Yao Y, Zha M, Sarun P, Du Y, Wang X, Zhong X, Pan T. | Eur J Pharmacol |
| 2026-08-17 | orforglipron | Safety and tolerability of orforglipron in Japanese people with type 2 diabetes Nauck MA, Horowitz M. | Lancet Diabetes Endocrinol |
| 2026-08-17 | orforglipron | Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial Yabe D, Shiraiwa T, Ugai H, Takeuchi M, Suzuki R. | Lancet Diabetes Endocrinol |
| 2026-08-17 | retatrutide | Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ. | Diabetes Obes Metab |
| 2026-08-14 | survodutide | Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN) Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. | Diabetes Ther |
| 2026-08-13 | tirzepatide | Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice Ding M, Li X, Wei Y, Wang J, Jiao B, Li C, Ma W, Peng Y, Shen J, Yu G, Gao C. | iScience |
| 2026-08-13 | liraglutide | Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial Caballero-Corbalán J, Lundkvist P, Espes D, Carlsson PO. | Diabetes Obes Metab |
| 2026-08-11 | semaglutide | Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting Liu T, Ren X, Li Y, Wang J, Chen J, Lin R, Zhang J. | J Enzyme Inhib Med Chem |
| 2026-08-07 | retatrutide | Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it Brown C. | BMJ |
| 2026-08-06 | tirzepatide | Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort Rosenior-Patten O, Lees Z, Rowe R, Hussain S, Ahmad E, Brooke E, Dix S, Maybury C. | Diabetes Obes Metab |
| 2026-08-06 | liraglutide | RETRACTED: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860 Paladugu L, Gharaibeh A, Kolli N, Learman C, Hall TC, Li L, Rossignol J, Maiti P, Dunbar GL. | Int J Mol Sci |
| 2026-08-06 | liraglutide | Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis Pałka W, Moćko P, Śladowska K, Holko P, Kawalec P. | J Endocrinol Invest |
| 2026-08-05 | liraglutide | A clinical and experimental investigation of liraglutide effects on the brain-kidney axis Greenwood MP, Alotaibi MI, Bárez-López S, Cantley NWP, Merritt S, Tatovic D, Murphy D. | Sci Adv |
| 2026-08-04 | liraglutide | Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis Zhu K, Liu H, He N, Wang H, Liu J, Zhang Q, Liu Z. | J Diabetes Investig |
| 2026-08-04 | orforglipron | Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary | JAMA |
| 2026-08-04 | mazdutide | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary | JAMA |
| 2026-08-03 | liraglutide | Effects of liraglutide on gut bacterial community dynamics Bull J, Durham PL, Mirza BS. | Microbiol Spectr |
| 2026-08-03 | liraglutide | Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment Anastasiou IA, Tentolouris K, Katsaouni A, Sarantis P, Mourouzis I, Rebelos E, Tentolouris N. | Int J Mol Sci |
| 2026-08-03 | liraglutide | Liraglutide affects mitochondrial function and histone acetylation through the NQO1/SIRT3 pathway in diabetic kidney disease Gao J, Lv X, Zhao P, Pan B, Liu J. | Mol Cell Biochem |
| 2026-08-03 | survodutide | Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, Schoelch C, Startseva E, Marshall SR, Alhussein A, Neff GW, Lawitz EJ, Bugianesi E, Anstee QM, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Alkhouri N, Younes R. | Hepatology |
| 2026-08-01 | liraglutide | Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy Tran BC, Zenno A, Mirza NM, Nadler E, Brady SM, Mayo OA, Lyman AP, Chung ST, Chen KY, Walter P, Cai H, Yang SB, Turner SA, Yanovski JA, Cheon BK. | Pediatr Obes |
| 2026-08-01 | dulaglutide | Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis Khalil I, Hossain MI, Akter MM, Wahid F, Khalid AA, Promi SA, Sayed MA, Rahman MT, Sarker P. | Clin Cardiol |
| 2026-08-01 | dulaglutide | Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes Marusic S, Staresinic M, Berkovic MC. | Int J Clin Pharmacol Ther |
| 2026-08-01 | orforglipron | Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. | JAMA |
| 2026-08-01 | orforglipron | Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes Gadde KM, Talebloo J, Heymsfield SB. | JAMA |
| 2026-08-01 | retatrutide | Retatrutide effects on diabetic rats' cognition Ferreira J. | Lab Anim (NY) |
| 2026-08-01 | mazdutide | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L, GLORY-2 Trial Investigators. | JAMA |
| 2026-08-01 | aleniglipron | Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Rosenstock J, Lingvay I, Ryan D, Jastreboff AM, Kushner R, Acosta A, Blevins TC, Choi M, Holmes FL, Smith T, Connery L, Li Y, Liu MK, Barth A, Butcher J, Civitarese A, Yue H, Coll B, ACCESS Trial Investigators. | Nat Med |
| 2026-07-31 | liraglutide | Correction: Gizdović et al. Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition. Cells 2026, 15, 1258 Gizdović I, Šošić-Jurjević B, Vlahović D, Ristić N, Lavrnja I, Filipović B, Marina L, Trifunović S. | Cells |
| 2026-07-30 | dulaglutide | Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels Maher OW, El-Sayed NM, El-Awady EE, El-Orabi NF, Radwan A. | Biomedicines |
| 2026-07-28 | tirzepatide | Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults Amioka M, Amioka H, Kinoshita H, Sairaku A, Nakano Y. | Diabetes Obes Metab |
| 2026-07-27 | orforglipron | Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling Deng Y, Guo Z, Yu L, Zhang J, Qian J, Wang J, Chen X, Xu Z, Wang D, Kong C. | Biochem Pharmacol |
| 2026-07-26 | semaglutide | Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE) Rodbard HW, Irace C, Lobo J, Makrilakis K, Priyadarshini P, Sivalingam S, Povedano ST, Bhargava A. | Diabetes Obes Metab |
| 2026-07-25 | liraglutide | Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications Katamine A, Oya J, Kondo Y, Hasegawa Y, Nakagami T. | J Diabetes Investig |
| 2026-07-24 | semaglutide | Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study Wei Y, Gong Y, Gong J, Zeng H, Zhong Z, Xiong Y, Li X. | J Obstet Gynaecol |
| 2026-07-23 | retatrutide | Retatrutide and the urinary tract infection signal: Is the answer hidden in timing? Koufakis T, Argyrakopoulou G, Kokkinos A, le Roux CW. | Eur J Intern Med |
| 2026-07-21 | orforglipron | Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects Li Y, Glotfelty EJ, Parekh P, Batsaikhan B, Luo W, Jackson SN, Harvey BK, Greig NH. | Cells |
| 2026-07-21 | orforglipron | Orforglipron: First Approval Shirley M. | Drugs |
| 2026-07-19 | semaglutide | Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial Timmons JG, Ghanim H, Boyle JG, Greenlaw N, Chaudhuri A, Batra MA, Lindsay RS, Jolly L, Bonner C, McConnachie A, Petrie JR, Dandona P. | Diabetes Obes Metab |
| 2026-07-18 | liraglutide | Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling Monir N, Galal O, Awad AS, Zaki HF, Saber MM. | Naunyn Schmiedebergs Arch Pharmacol |
| 2026-07-16 | liraglutide | Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data Cannon EJ, Wang W, Norby FL, Walker RF, Kulasingam S, Chow LS, Farley JF, Lutsey PL. | Br J Clin Pharmacol |
| 2026-07-15 | semaglutide | Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison Mantovani A, Targher G. | Diabetes Obes Metab |
| 2026-07-15 | exenatide | Exenatide Attenuates Doxorubicin-Induced Acute Hepatic Injury Through Modulation of SIRT1-HMGB1 Signaling and Oxidative Stress Karakullukcu HK, Gül SS, Aygun H, Kalın M, Karakullukcu M, Arslan A, Özkan ÖF, Ercan G. | Pharmaceuticals (Basel) |
| 2026-07-15 | orforglipron | Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis Alper A, Fagin A, Karthikeyan A, Karp A, Terashima R, Murli H, Gershon A, Faillace R. | High Blood Press Cardiovasc Prev |
| 2026-07-14 | tirzepatide | Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series Nadolsky S, Kessel S, Krumm ZA, Tinsley GM. | Obes Pillars |
| 2026-07-14 | liraglutide | Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery Ouyang Y, Zhong W, Chen L, Tang W, Cao X, Chu X, Zhu D, Feng W. | Obes Surg |
| 2026-07-14 | orforglipron | Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials Horn DB, Shukla AP, Huang H, Twum E, Allen SE, Kis SG. | Obes Pillars |
| 2026-07-13 | semaglutide | Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey Kjærgaard K, Graabæk T, Thomsen RW, Cardél LG, Bramming M, Pottegård A, Lundby C. | Diabetes Obes Metab |
| 2026-07-13 | tirzepatide | Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database Guo X, Zhang J, Li Q, Ye Z, Yuan S. | Diabetes Obes Metab |
| 2026-07-13 | tirzepatide | Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis Spiazzi BF, Zingano CP, Colpani V, Gerchman F. | Diabetes Res Clin Pract |
| 2026-07-13 | liraglutide | Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio Ziebarth J, Babinski TP, Moreira FF, Tartari APS, Zago A, da Costa SP, Pinheiro MF, Mainardes RM. | Int J Biol Macromol |
| 2026-07-13 | liraglutide | Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition Gizdović I, Šošić-Jurjević B, Vlahović D, Ristić N, Lavrnja I, Filipović B, Trifunović S. | Cells |
| 2026-07-13 | orforglipron | Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics Mohammad A, Dashti M, Malik MDZ, Rajan R, Al-Mulla F. | Int J Biol Macromol |
| 2026-07-13 | cagrilintide | Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M. | Ann Med Surg (Lond) |
| 2026-07-10 | tirzepatide | Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight Gibble TH, Leith A, Harrison L, Gerber C, Raikar SK, Seth E, Artime E. | Obes Pillars |
| 2026-07-10 | liraglutide | Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response Zhang L, Wu W, Lu H. | J Vis Exp |
| 2026-07-09 | tirzepatide | Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey Gibble TH, Al-Zubeidi T, Gerber C, Collins E, Vardavoulia A, Lin A, He X, Shepherd M, Fitch A, Bays H. | Obes Pillars |
| 2026-07-09 | retatrutide | Retatrutide fact check: Has a man died after taking the unapproved weight loss jab? Mahase E. | BMJ |
| 2026-07-08 | semaglutide | Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists Chen SC, Wang TJ, Chou CK, Lee C. | Diabetes Obes Metab |
| 2026-07-08 | semaglutide | Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes Skandov MD, Christensen KM, Dalin DA, Unkerskov J, Brønden A, Lund M, Christensen MB, Karstoft K. | Diabetes Obes Metab |
| 2026-07-08 | orforglipron | Orforglipron (Foundayo) for adults with obesity Zhou Q, Li G, Wang MW. | Trends Pharmacol Sci |
| 2026-07-07 | ecnoglutide | Ecnoglutide: First Approvals Shirley M. | Drugs |
| 2026-07-06 | semaglutide | Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials Ukkonen M, Kivivuori A, Starckjohann P, Lammi P, Junttila A, Panula V. | Diabetes Obes Metab |
| 2026-07-06 | tirzepatide | Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers Berry SA, Goodman IR, McNally E, Elliott J, Iqbal A. | Diabetes Obes Metab |
| 2026-07-06 | mazdutide | Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, Ahsan A, Dutta D. | Diabetes Obes Metab |
| 2026-07-03 | liraglutide | Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice Tan AJ, Li TR, Yang JJ, Li XL, Li WQ, Yu JW. | J Diabetes Investig |
| 2026-07-03 | orforglipron | Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Morse BL, Coutant DE, Ma X, Raha S, Aithal K, Nicoll C, Rougée LRA, Bhattachar S. | Clin Pharmacol Ther |
| 2026-07-03 | albiglutide | Contractile effects of albiglutide in the human and mouse atrium Neumann J, Jarikova M, Kirchhefer U, Hofmann B, Gergs U. | Front Endocrinol (Lausanne) |
| 2026-07-02 | liraglutide | Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling Andrés-Rozas M, Aristu-Zabalza P, Chullo G, Liu G, Fundora Y, Villa R, Lopez J, Folguera C, Fernández-Iglesias A, Guixé-Muntet S, Gracia-Sancho J. | Biomed Pharmacother |
| 2026-07-02 | liraglutide | Liraglutide Potently Protects Against Streptozotocin-Induced Islet Injury Associated with Inhibition of HMGB1 Release Shi Y, Yang X, Luo X, Yang J, Zhang Y, Chen G, Hou L. | Cells |
| 2026-07-01 | dulaglutide | Contractile effects of dulaglutide in the human atrium Neumann J, Jarikova M, Hofmann B, Kirchhefer U, Gergs U. | Naunyn Schmiedebergs Arch Pharmacol |
| 2026-07-01 | orforglipron | Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials Hageen AW, Gadelmawla AF, Saleh AO, Mohamed MR, Abdallfatah A, Elsekhary A, El-Nemr AF, Eladawi S, Maihoub O, Abdulhay H, Turkmani M, Abdelazeem B, Fonarow GC. | Endocrinol Diabetes Metab |
| 2026-07-01 | orforglipron | Orforglipron Calcium | Am J Health Syst Pharm |
| 2026-07-01 | retatrutide | Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats Keskin U, Altın E, Kara MK, Tekin B, Çakırçoban KN, Özatik FY, Arı NS, Sezgin AK, Güngor E. | Behav Brain Res |
| 2026-07-01 | cagrilintide | Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials Hamarsheh S, Jaber AR, Abu-Khazneh O, Andonie CR, Majadleh S, Zahran A, Ayesh H. | Endocrinol Diabetes Metab |
| 2026-06-29 | retatrutide | Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. | High Blood Press Cardiovasc Prev |
| 2026-06-29 | lixisenatide | Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria Ozturk S, Akyol EMB. | J Clin Med |
| 2026-06-26 | semaglutide | From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease Maggioni AP, Orso F, Lucci D, De Luca L, Colivicchi F. | Int J Cardiol |
| 2026-06-25 | liraglutide | Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion Saponaro C, Imbernon M, Louvet I, Deligia E, Chen S, Davies I, Acosta-Montalvo A, Moreno-Lopez M, Wemelle E, Kothegala L, Porteiro B, Auger F, Zubiaga L, Dellalau N, Thevenet J, Mühlemann M, Pasquetti G, Gmyr V, Pfrieger FW, Nogueiras R, Schwaninger M, Rorsman P, Staels B, Kerr-Conte J, Knauf C, Jones B, Pattou F, Prevot V, Bonner C. | Diabetologia |
| 2026-06-23 | orforglipron | Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials Wharton S, Stefanski A, Chen J, Rao G, Twum EA, Denning M. | Diabetes Obes Metab |
| 2026-06-22 | exenatide | Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial The Editors Of The Lancet. | Lancet |
| 2026-06-22 | orforglipron | Fast-tracked innovation: orforglipron approval under the FDA's National Priority Voucher program Sheikh M, Fatima SH, Bilal Z, Amin JHJ. | Ann Med Surg (Lond) |
| 2026-06-22 | survodutide | Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C. | Diabetes Obes Metab |
| 2026-06-21 | liraglutide | Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes Mayyas F. | J Diabetes Complications |
| 2026-06-20 | dulaglutide | Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial Šiarnik P, Rádiková Ž, Kollár B, Kutšálová M, Penesová A, Havranová A, Imrich R, Vlček M, Žitňanová I, Krastev G, Turčáni P. | Neurol Ther |
| 2026-06-19 | tirzepatide | Insufficient exclusion of infectious and biofilm-related complications in reported tirzepatide-associated filler nodules Pitak-Arnnop P. | JAAD Case Rep |
| 2026-06-19 | orforglipron | Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial Malhotra A, Gottlieb DJ, Kundel V, Woehrle H, Chakladar S, Firmino Goncalves L, Calamai G. | Contemp Clin Trials Commun |
| 2026-06-17 | tirzepatide | Inflammation-mediated facial nodules to compounded tirzepatide Moore LC, Hurley K, Moore AY. | JAAD Case Rep |
| 2026-06-17 | tirzepatide | Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey Gibble TH, Makin H, Gerber C, Bottomley C, He X, Pisani S, Shepherd M, Collins E, Golden A, Bays H. | Obes Pillars |
| 2026-06-17 | ecnoglutide | Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants Li F, Du C, Yu Q, Feng S, Cai L, Chen Z, Zou Q, Guo W, Du D, Hu F, Liu X, Huang Y, Shi S, Shi W, Guan L, Yang L, Zheng Q, Li Y, Liu R, Yang M. | Diabetes Obes Metab |
| 2026-06-15 | exenatide | Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia Wu TH, Kuo CS, Chen HS. | J Chin Med Assoc |
| 2026-06-11 | exenatide | Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus Gao Y, Hong X, Yang K, Le Y, Wei R, Yang J, Hong T, Tian Q. | J Clin Transl Endocrinol |
| 2026-06-09 | retatrutide | Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports Lang K. | BMJ |
| 2026-06-08 | dulaglutide | Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study Ulrich FS, Frost Nielsen M, Napoli N, Burden AM. | Lancet Reg Health Eur |
| 2026-06-08 | orforglipron | Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y, ACHIEVE-2 Trial Investigators. | Lancet |
| 2026-06-08 | cagrilintide | A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance Ludwig MQ, Coester B, Gordian D, Hassan S, Tomlinson AJ, Toure MH, Christensen OP, Lommi G, Moltke-Prehn A, Brown JM, Belmont-Rausch DM, Bau S, Bodur C, Gowda A, Wu I, Kernodle S, Dong V, Ayensu-Mensah M, Sabatini PV, Shin JH, Kirigiti M, Egerod KL, Le Foll C, Lundh S, Gerstenberg MK, Lutz TA, Kievit P, Secher A, Raun K, Myers MG, Pers TH. | Nat Metab |
| 2026-06-07 | cagrilintide | Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study Aroda VR, Buzzetti R, Dalskov SM, Jain AB, Larsen JH, Mathieu C, Pratley RE, Videmark A, Watt T, Buse JB. | Lancet Diabetes Endocrinol |
| 2026-06-07 | cagrilintide | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW, Haluzík M, Lingvay I, Pedersen SD, Pratley RE, Jain AB, REIMAGINE 2 study group. | Lancet Diabetes Endocrinol |